Association between somatization subscale score and serotonin transporter availability in healthy volunteers—a single photon emission computed tomography study with [123I] ADAM

Chou, Ming Hui; Chen, Kao Chin; Yeh, Tzung Lieh; Lee, I. Hui; Yao, Wei Jen; Chen, Po See; Chang, Kang-Wei; Liao, Mei; Yang, Yen Kuang

doi:10.1007/s00213-011-2431-0

Cited by 4 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The availability of serotonin transporter (SERT) was assessed using single photon emission computed tomography (SPECT) with [I-123]-ADAM 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine, a radioligand confirmed to have a high selectivity for imaging SERT availability in SPECT [ 12 , 13 ]. We previously showed [ 14 ] the test-retest reproducibility of [I-123]-ADAM for different durations and reconfirmed [ 15 ] the correlation between [I-123]-ADAM-derived SERT activity and somatization symptoms. Only a few studies focus on the association between SERT activity and obesity in patients with an eating disorder.…”

Section: Introductionmentioning

confidence: 68%

Comparison of brain serotonin transporter using [I-123]-ADAM between obese and non-obese young adults without an eating disorder

Chang

Yang

et al. 2017

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Cerebral serotonin metabolism has an important but controversial role in obesity. However, it is not given enough attention in morbidly obese young adults. We used single photon emission computed tomography (SPECT) with [I-123]-labeled 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM) to investigate changes in serotonin transporter (SERT) availability in 10 morbidly obese young adults without an eating disorder (M/F = 5/5, body mass index (BMI): 40.3 ± 4.1 kg/m2, percentage of body fat (BF%): 46.0 ± 3.9%) and 10 age- and sex-matched non-obese controls (BMI: 20.3 ± 1.2 kg/m2, BF%: 20.6 ± 8.9%). All participants underwent SPECT at 10 min and 6 h after an injection of 200 MBq of [I-123]-ADAM. The SERT binding site (midbrain) was drawn with cerebellum normalization. The BF% and fat distribution were measured using dual-energy X-ray absorptiometry. The midbrain/cerebellum SERT binding ratios (2.49 ± 0.46 vs. 2.47 ± 0.47; p = 0.912) at 6 h were not significantly different between groups, nor was the distribution of the summed images at 10 min (1.36 ± 0.14 vs. 1.35 ± 0.11; p = 0.853). There were no significant correlations between midbrain/cerebellum SERT binding ratio and age, BMI, BF%, or fat distribution. No significant difference in SERT availability in the midbrain between morbidly obese and non-obese young adults without an eating disorder indicates an unmet need for investigating the role of cerebral serotonin in obesity.

show abstract

Section: Introductionmentioning

confidence: 68%

Comparison of brain serotonin transporter using [I-123]-ADAM between obese and non-obese young adults without an eating disorder

Chang

Yang

et al. 2017

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…The serotonin (5-hydroxytryptamine, 5-HT) transporter (5-HTT) has a crucial role in regulating emotional and reward processing. 1 , 2 , 3 Changes in 5-HTT availability and thus synaptic serotonin levels have been associated with stress-related diseases such as mental and metabolic disorders including obesity. 4 , 5 , 6 , 7 , 8 , 9 , 10…”

Section: Introductionmentioning

confidence: 99%

Serotonin transporter gene promoter methylation status correlates with in vivo prefrontal 5-HTT availability and reward function in human obesity

et al. 2017

View full text Add to dashboard Cite

A polymorphism in the promoter region of the human serotonin transporter (5-HTT)-coding SLC6A4 gene (5-HTTLPR) has been implicated in moderating susceptibility to stress-related psychopathology and to possess regulatory functions on human in vivo 5-HTT availability. However, data on a direct relation between 5-HTTLPR and in vivo 5-HTT availability have been inconsistent. Additional factors such as epigenetic modifications of 5-HTTLPR might contribute to this association. This is of particular interest in the context of obesity, as an association with 5-HTTLPR hypermethylation has previously been reported. Here, we tested the hypothesis that methylation rates of 14 cytosine–phosphate–guanine (CpG) 5-HTTLPR loci, in vivo central 5-HTT availability as measured with [11C]DASB positron emission tomography (PET) and body mass index (BMI) are related in a group of 30 obese (age: 36±10 years, BMI>35 kg/m2) and 14 normal-weight controls (age 36±7 years, BMI<25 kg/m2). No significant association between 5-HTTLPR methylation and BMI overall was found. However, site-specific elevations in 5-HTTLPR methylation rates were significantly associated with lower 5-HTT availability in regions of the prefrontal cortex (PFC) specifically within the obese group when analyzed in isolation. This association was independent of functional 5-HTTLPR allelic variation. In addition, negative correlative data showed that CpG10-associated 5-HTT availability determines levels of reward sensitivity in obesity. Together, our findings suggest that epigenetic mechanisms rather than 5-HTTLPR alone influence in vivo 5-HTT availability, predominantly in regions having a critical role in reward processing, and this might have an impact on the progression of the obese phenotype.

show abstract

In-vivo serotonin transporter availability and somatization in healthy subjects

Bresch

Rullmann

Luthardt

et al. 2016

Personality and Individual Differences

View full text Add to dashboard Cite

Association between somatization subscale score and serotonin transporter availability in healthy volunteers—a single photon emission computed tomography study with [123I] ADAM

Abstract: This result reconfirmed the correlation between central serotonergic activity and the intensity of somatization symptoms, even in healthy participants. However, a gender difference exists in this correlation.

Cited by 4 publications

References 46 publications

Comparison of brain serotonin transporter using [I-123]-ADAM between obese and non-obese young adults without an eating disorder

Comparison of brain serotonin transporter using [I-123]-ADAM between obese and non-obese young adults without an eating disorder

Serotonin transporter gene promoter methylation status correlates with in vivo prefrontal 5-HTT availability and reward function in human obesity

In-vivo serotonin transporter availability and somatization in healthy subjects

Contact Info

Product

Resources

About